Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximal tolerated dose of idarubicin for
chemoembolization of non resectable non metastatic hepatocellular carcinoma.